262 related articles for article (PubMed ID: 27095757)
1. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus resistance to the new direct-acting antivirals.
Esposito I; Trinks J; Soriano V
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
[TBL] [Abstract][Full Text] [Related]
3. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.
Premoli C; Aghemo A
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
Li Z; Chen ZW; Ren H; Hu P
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
[TBL] [Abstract][Full Text] [Related]
5. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
6. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
Chayama K; Hayes CN
Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
[TBL] [Abstract][Full Text] [Related]
7. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
8. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
9. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
Li DK; Chung RT
Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Wang Y; Rao HY; Xie XW; Wei L
Chin Med J (Engl); 2015 Oct; 128(19):2625-31. PubMed ID: 26415801
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance.
Jiménez-Pérez M; González-Grande R; España Contreras P; Pinazo Martínez I; de la Cruz Lombardo J; Olmedo Martín R
World J Gastroenterol; 2016 Aug; 22(29):6573-81. PubMed ID: 27547001
[TBL] [Abstract][Full Text] [Related]
12. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
Colpitts CC; Baumert TF
Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
[TBL] [Abstract][Full Text] [Related]
13. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.
Sagnelli E; Starace M; Minichini C; Pisaturo M; Macera M; Sagnelli C; Coppola N
Infection; 2018 Dec; 46(6):761-783. PubMed ID: 30084057
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Mansour M; Hill L; Kerr J
Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
[TBL] [Abstract][Full Text] [Related]
15. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review.
Onorato L; Pisaturo M; Starace M; Minichini C; Di Fraia A; Astorri R; Coppola N
Viruses; 2021 Mar; 13(3):. PubMed ID: 33800289
[TBL] [Abstract][Full Text] [Related]
16. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
17. New Therapies for Hepatitis C Virus.
Polenakovik H
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
[TBL] [Abstract][Full Text] [Related]
18. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
Sarrazin C
J Hepatol; 2016 Feb; 64(2):486-504. PubMed ID: 26409317
[TBL] [Abstract][Full Text] [Related]
19. [Progress in Examination and Treatment of Hepatitis C Virus].
Suda G; Sakamoto N
Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.
Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P
J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
